Skip to Content

Uroxatral (alfuzosin) Disease Interactions

There are 5 disease interactions with Uroxatral (alfuzosin):

Major

Alfuzosin (applies to Uroxatral) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Alfuzosin is contraindicated for use in patients with moderate or severe hepatic impairment (Child Pugh B and C). The pharmacokinetics of alfuzosin have not been studied in patients with mild hepatic impairment and caution should be exercised if it is administered to such patients.

Moderate

Alfuzosin (applies to Uroxatral) QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome

Alfuzosin should be used with caution in patients with acquired or congenital QT prolongation, or who are taking medications that prolong the QT interval.

Moderate

Alfuzosin (applies to Uroxatral) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Caution should be exercised when alfuzosin is administered in patients with severe renal impairment as safety data is limited on these patients (CrCl < 30 mL/min).

Moderate

Alpha-1 blockers (applies to Uroxatral) hypotension

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Syncope, Dehydration

Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations. Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose. However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days. Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects. Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes. Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs. Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling. During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur. Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized. If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.

References

  1. "Product Information. Cardura (doxazosin)." Pfizer US Pharmaceuticals, New York, NY.
  2. Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976): 1293-4
  3. "Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977): 1-2
  4. Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994): 22-31
  5. Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994): 1067-74
  6. Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995): 11-8
  7. Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974): 171-4
  8. "Product Information. Hytrin (terazosin)." Abbott Pharmaceutical, Abbott Park, IL.
  9. Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):
  10. Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996): 406-15
  11. Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977): 429-33
  12. Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982): 455
  13. "Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim, Ridgefield, CT.
  14. Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984): 219-28
View all 14 references
Moderate

Antiadrenergic agents (applies to Uroxatral) cataracts

Moderate Potential Hazard, Moderate plausibility.

Intraoperative Floppy Iris Syndrome has been observed during cataract surgery in some patients on or previously treated with antiadrenergic agents. If a patient is undergoing cataract surgery, the ophthalmologist should be prepared for possible modifications of the surgical technique (iris hooks, iris dilator rings). There does not appear to be a benefit in stopping antiadrenergic agents therapy prior to the cataracts surgery.

Uroxatral (alfuzosin) drug interactions

There are 451 drug interactions with Uroxatral (alfuzosin)

Uroxatral (alfuzosin) alcohol/food interactions

There are 2 alcohol/food interactions with Uroxatral (alfuzosin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.